Enzychem Life Science(CEO Son Ki-young, 183490) announced on the 5th that the phase 2 clinical trial plan (IND) for atopic dermatitis treatment submitted to the Ministry of Food and Drug Safety has been approved.
This clinical trial by ENGICEM Life Sciences aims to develop an oral atopic dermatitis treatment. After oral administration of EC-18 for 16 weeks to 120 patients with moderate or severe atopic dermatitis, the change in Eczema Severity Index (EASI) was conducted. Efficacy and safety will be evaluated through , and it is scheduled to be conducted for approximately two years at Korea University Ansan Hospital and 10 other institutions in Korea.
NG Chem Life Science’s non-clinical research results in an atopic dermatitis animal model of EC-18 were published in the SCI-level academic journal Scientific Reports last October. In the study, EC-18 significantly reduced the EASI score in a mouse model that induced atopic dermatitis, improved the thickened epidermis caused by hyperkeratosis, lowered allergic reactions, and restored the balance of immune responses.
NG Chem Life Science New Drug Development Research Institute said, “EC-18 will be developed as a drug for oral administration with high user convenience. It is a substance whose safety has already been secured through phase 1 clinical trials, and has no resistance or side effects such as steroids or immunosuppressants. “We expect to solve the unmet medical needs of patients with severe atopic dermatitis by improving symptoms such as skin itching, erythema, and erosion when taken.”
ENGICHEM Life Sciences is currently developing a treatment for oral mucositis (CRIOM), acute radiation syndrome (ARS), and atopic dermatitis based on the new drug candidate EC-18, and has recently developed new ADC and DAC treatments. The pipeline was launched.
For oral mucositis treatment, we are actively pursuing out-licensing by recruiting a new global new drug business development professional familiar with Big Pharma and the FDA.
As a treatment for acute radiation syndrome (ARS), a non-clinical research paper proving the efficacy of EC-18 for gastrointestinal damage caused by radiation was published last October in Radiation Research (SCI level), the official journal of the American Society of Radiology, a world-renowned academic journal. There is a bar. Currently, non-clinical trials for Phase 2 equivalent primate testing with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and SRI are underway.
In relation to this, the Korea Aerospace Administration (KASA) was established in Korea in June 2024 to secure innovative aerospace technology and protect the public from space risks, and Hanwha Aerospace and Korea Aerospace Industries (KAI) are involved in the aerospace industry. It is actively advancing and emerging as a global company. However, no company has yet developed a treatment for Acute Radiation Syndrome (ARS) to solve the radiation exposure problem, and with the advent of space travel, ENGICEM Life Science’s treatment is receiving particular attention.
And last August, the anti-cancer efficacy of EC-18 was revealed in a non-clinical study on an animal model of Non-Small Cell Lung Cancer (NSCLC), and was published in ‘Biomedicine & The paper was published in ‘Pharmacotherapy’ (Impact Factor: 6.9).
